NCT04979910View on ClinicalTrials.gov

Targeting IL-17A for Treatment-Resistant Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions
Major Depressive Disorder
Interventions
DRUG

Ixekizumab

a monoclonal antibody (mAb) against interleukin 17A (IL-17A)

Trial Locations (1)

10025

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT04979910 - Targeting IL-17A for Treatment-Resistant Depression | Biotech Hunter | Biotech Hunter